Last reviewed · How we verify

M518101

Maruho Co., Ltd. · Phase 3 active Small molecule

M518101 is a topical agent developed for dermatological use, likely targeting inflammatory or proliferative skin conditions.

At a glance

Generic nameM518101
Also known asvitamin D3, psoriasis treatment
SponsorMaruho Co., Ltd.
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

M518101 is an investigational compound in phase 3 development by Maruho Co., Ltd., a Japanese pharmaceutical company specializing in dermatology. Without disclosed mechanism details, the drug's exact molecular target and therapeutic pathway remain proprietary. Given Maruho's focus on dermatological treatments, M518101 is likely formulated for topical application to treat skin disorders.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: